A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
Clinical trial NCT07100106 · RECRUITING
Trial details
- NCT number
- NCT07100106
- Sponsor
- Genentech, Inc.
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-10-07
- Primary completion
- 2028-08-31
- Enrollment
- 285
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.